Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 79Other hematologic neoplasm 59Thoracic 30CNS 26Sarcoma 21Myeloid 12Genitourinary 9Classical hematology 8Plasma cell 6Endocrine 4Other solid neoplasm 3Gynecologic 3Dermatologic 3Breast 3Tumor-Agnostic 1NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 7Specimen Handling 7Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 3cabozantinib 3X-Rays 3Everolimus 3Sunitinib 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2romidepsin 1peposertib 1pembrolizumab 1pazopanib 1olaparib 1fludarabine 1belinostat 1aldesleukin 1Sorafenib 1Salts 1Photons 1Octreotide 1Nivolumab 1Lactones 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Etoposide × NET × Clear all
NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡